Milsaperidone

Brand names: Bysanti · Active ingredient: Milsaperidone

In short: BYSANTI™ is indicated for the: Treatment of schizophrenia in adults . Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults .

Forms & strengthsTablets: • 1 mg: yellow, oval shaped, debossed with "1" on one side and “” logo on other side • 2 mg: pink oblong oval shaped, debossed with "2" on one side and “” logo on other side • 4 mg: blue oval shaped, debossed with "4" on one side and “” logo on other …
LabelVanda Pharmaceuticals Inc.
Label updatedJul 01, 2026

What is Milsaperidone used for?

BYSANTI™ is indicated for the:

Treatment of schizophrenia in adults .

Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults .

⚠ Boxed warning (FDA's strongest warning)

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. BYSANTI is not approved for the treatment of patients with dementia-related psychosis .

Milsaperidone dosage

Table 1 includes the recommended BYSANTI dosage for the treatment of schizophrenia and the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.

Titrate BYSANTI to reduce the risk of orthostatic hypotension .

Administer BYSANTI orally with or without food .

Table 1: BYSANTI Recommended Dosage in Adults with Schizophrenia or Manic or Mixed Episodes Associated with Bipolar I Disorder

* Patients with schizophrenia may either (1) follow the recommended titration schedule, OR (2) starting on Day 5, continue 6 mg twice daily BYSANTI dosing. As needed, titrate subsequent doses based on tolerability and response within the recommended maintenance dosing range of 6 mg to 12 mg twice daily.

Population | Titration Schedule | Recommended Maintenance Dosage

Day1 | Day 2 | Day3 | Day 4 | Day 5 | Day 6 | Day 7

Schizophrenia | 1mg twice daily | 2 mg twice daily | 4 mg twice daily | 6 mg twice daily | 8 mg twice daily* | 10 mg twice daily* | 12 mg twice daily* | 6 mg to 12 mgtwice daily

Manic or MixedEpisodesAssociated withBipolar IDisorder | 1 mg twice daily | 3 mg twice daily | 6 mg twice daily | 9 mg twice daily | 12 mg twice daily | Titrationcomplete | 12 mgtwice daily

Consider CYP2D6 genetic testing to determine the patient’s CYP2D6 metabolizer status prior to BYSANTI dosing. Follow the titration schedule outlined in Table 2 for dosage recommendations in CYP2D6 poor metabolizers for the treatment of schizophrenia and the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults .

Table 2: BYSANTI Recommended Dosage in Adults, with Schizophrenia or Manic or Mixed Episodes Associated with Bipolar I Disorder, Who are CYP2D6 Poor Metabolizers

* Patients with schizophrenia may either (1) follow the recommended titration schedule, OR (2) starting on Day 3, initiate and continue 3 mg twice daily BYSANTI dosing. As needed, titrate subsequent doses based on tolerability and response within the recommended maintenance dosing range of 3 mg to 6 mg twice daily.

Population | Titration Schedule | Recommended Maintenance Dosage

Day 1 | Day 2 | Day 3 | Day 4

Schizophrenia | 1mg twicedaily | 2 mg twicedaily | 4 mg twicedaily* | 6 mg twicedaily* | 3 mg to 6 mgtwice daily

Manic or MixedEpisodesAssociated withBipolar IDisorder | 1 mg twicedaily | 3 mg twicedaily | 6 mg twicedaily | Titration complete | 6 mgtwice daily

The recommended BYSANTI dosage in patients with mild hepatic impairment (HI) is the same as those with normal hepatic function. Consider a lower maintenance dosage in patients with moderate HI. BYSANTI is not recommended in patients with severe HI . …

How to take Milsaperidone — instructions & advice from the label

QTc Interval Prolongation

Patients should be advised to consult their healthcare provider immediately if they feel faint, lose consciousness, or have heart palpitations. Patients should be counseled not to take BYSANTI with other drugs that cause QT interval prolongation . Patients should be told to inform their healthcare provider that they are taking BYSANTI before any new drug is taken.

Neuroleptic Malignant Syndrome

Counsel patients and caregivers about a potentially fatal neuroleptic malignant syndrome (NMS) that has been reported with administration of antipsychotic drugs. Advise patients and caregivers to contact the healthcare provider or to report to the emergency room if they experience signs and symptoms of NMS .

Tardive Dyskinesia

Counsel patients on the signs and symptoms of tardive dyskinesia and to contact their healthcare provider if these abnormal movements occur .

Metabolic Changes

Educate patients of metabolic changes, how to recognize symptoms of hyperglycemia and diabetes mellitus, and the need for specific monitoring, including blood glucose, lipids, and weight. …

Warnings & precautions

Do not take this medicine if: BYSANTI is contraindicated in individuals with a known hypersensitivity reaction to milsaperidone or the inactive ingredients in BYSANTI. Anaphylaxis, angioedema, and other hypersensitivity reactions have been reported .

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks) largely in patients taking atypical antipsychotic drugs for dementia-related psychosis, revealed a risk of death in antipsychotic drug-treated patients was 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the incidence of death in antipsychotic drug-treated patients was about 4.5%, compared to an incidence of about 2.6% in placebo-treated patients. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.

BYSANTI is not approved for the treatment of patients with dementia-related psychosis .

In placebo-controlled trials in elderly patients with dementia-related psychosis treated with risperidone, aripiprazole, or olanzapine had a higher incidence of stroke and transient ischemic attack, including fatal stroke compared to those treated with placebo.

BYSANTI is not approved for the treatment of patients with dementia-related psychosis .

In a QTc study, the use of iloperidone (iloperidone and milsaperidone rapidly interconvert in vivo) was associated with QTc interval prolongation, especially with concomitant use of a CYP2D6 inhibitor or a CYP3A4 inhibitor. No cases of torsade de pointes or other severe cardiac arrhythmias were observed in the iloperidone studies. …

Milsaperidone side effects

The following adverse reactions are discussed in more detail in other sections of the labeling:

Increased Mortality in Elderly Patients with Dementia-Related Psychosis

Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with Dementia-Related Psychosis

QT Prolongation

Neuroleptic Malignant Syndrome (NMS)

Tardive Dyskinesia

Metabolic Changes

Orthostatic Hypotension and Syncope

Falls

Seizures

Leukopenia, Neutropenia and Agranulocytosis

Hyperprolactinemia

Body Temperature Regulation

Dysphagia

Priapism

Potential for Cognitive and Motor Impairment

Intraoperative Floppy Iris Syndrome

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trial of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The safety of BYSANTI has been established from adequate and well-controlled studies of iloperidone tablets (referred to hereafter as “iloperidone” (iloperidone and milsaperidone rapidly interconvert in vivo)) in adults with schizophrenia or with mixed or manic episodes associated with bipolar I disorder . Below is a display of the adverse reactions of iloperidone in these adequate and well-controlled studies. …

Drug interactions

Table 7 presents clinically significant drug interactions where concomitant use of another drug affects BYSANTI.

Table 7: Clinically Significant Drug Interactions: Concomitant Use of Other Drugs Affect the Use of BYSANTI

Strong CYP2D6 Inhibitors

Prevention or Management | Reduce the dosage of BYSANTI when administered with a strong CYP2D6 inhibitor .

When the strong CYP2D6 inhibitor is stopped in BYSANTI-treated patients, gradually increase the BYSANTI dosage to the pre-inhibitor dosage.

Mechanism and Clinical Effect(s) | Milsaperidone and iloperidone are CYP2D6 substrates (iloperidone and milsaperidone rapidly interconvert in vivo). Strong CYP2D6 inhibitors increased exposure of milsaperidone and iloperidone , which may increase the risk of BYSANTI-associated adverse reactions.

Strong CYP3A4 Inhibitors

Prevention or Management | Reduce the dosage of BYSANTI when administered with a strong CYP3A4 inhibitor .

When the strong CYP3A4 inhibitor is stopped in BYSANTI-treated patients, gradually increase the BYSANTI dosage to the pre-inhibitor dosage.

Mechanism and Clinical Effect(s) | Milsaperidone and iloperidone are CYP3A4 substrates. …

About this medicine

The active ingredient in BYSANTI is milsaperidone, an atypical antipsychotic that is in the piperidinyl-benzisoxazole derivative chemical class. Its chemical name is benzenemethanol, 4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-α- methyl-, (αS)-. Its molecular formula is C24H29FN2O4 and its molecular weight is 428.50. Milsaperidone is a white to off-white finely crystalline powder. The structural formula of milsaperidone is:

Milsaperidone is a white to off-white finely crystalline powder.

BYSANTI (milsaperidone) tablets are for oral administration only. Coated tablets contain 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, or 12 mg of milsaperidone. Inactive ingredients are the following: colloidal silicon dioxide, crospovidone, hydroxypropylmethylcellulose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and water (removed during processing). …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 254a1c01-4a4c-4bdd-85d6-1f23f2e4e6f8. Read the full official label on DailyMed.

Related medicines

Sertraline Escitalopram Bupropion Fluoxetine Trazodone Duloxetine Prednisone Buspirone